 Connection
Eric Wu to Drug Administration Schedule
This is a "connection" page, showing publications Eric Wu has written about Drug Administration Schedule.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.128 |
|
|
|
-
Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):326-35.
Score: 0.075
-
Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L. Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Oncol Pract. 2013 Sep; 9(5):e212-9.
Score: 0.022
-
Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9.
Score: 0.016
-
Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|